Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 1998

View Archived Issues

Fujisawa: FY 1998 highlights

Pentoxifylline shows efficacy in treatment of pruritus in HIV-infected patients

Compounds for bone diseases, neuropathy discovered at Takeda

New protein farnesyltransferase inhibitors prepared by Zeneca

Company Profile: ImmPheron

Imutech and Harvard Medical School join forces for clotrimazole development

Steroidogenesis Inhibitors seeks Romanian approval to begin pediatric trial with Anticort

Novartis and Trega sign agreement for obesity and diabetes research

Inex: Q1 1998 highlights

Schering AG presents factor Xa/thrombin inhibitors

Protein tyrosine or serine/threonine kinase inhibitors in development at Novartis

Agents for tumors and tumor metastasis synthesized at Ishihara Sangyo

Pfizer reports AChE inhibitors with memory-enhancing effects

Integrilin launched in first market today

New topical corticosteroid available in U.S. for ophthalmic use

Muscarinic receptor ligands from AHP with potential in treating cognition disorders

MMP/TNF-alpha convertase inhibitors disclosed by Agouron

JTV-519, a novel cardioprotective agent, and propranolol protect myocardium following SAH

FDA approves ADCON-L

ECG and hemodynamic evaluation of dronedarone, a new antiarrhythmic agent

Alzheimer's disease treatment launched in U.K.

Emisphere Technologies begins phase II trial with oral heparin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.